<DOC>
	<DOCNO>NCT01304693</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , effect treatment ocular outcome follow single intravitreal administration ESBA1008 compare LUCENTIS® patient exudative age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>ESBA1008 Safety , Tolerability Effects Wet Age-Related Macular Degeneration ( AMD ) Patients</brief_title>
	<detailed_description>This study conduct two part . In Part 1 , patient initially randomize ( 5:2 ) receive either ESBA1008 low dose ( Dose A ) LUCENTIS . After Safety Committee review , second cohort enrol randomize ( 5:2 ) next high dose ESBA1008 ( Dose B ) . Safety review enrollment patient third cohort ( Dose C ) fourth cohort ( Dose D ) conduct manner . Part 2 , expansion period , consist 2 arm . In first arm patient randomize receive ESBA1008 Dose C LUCENTIS ( 43:44 ) . In second arm , patient randomize ESBA1008 Doses A : B : D : Lucentis ( 5:30:35:9 ) . All enrol patient ( Part 1 Part 2 ) evaluate safety efficacy across 13 study visit , include Screening , Randomization , 11 post- treatment follow-up visit ( Day 1 Month 6 ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Provide write informed consent . Primary subfoveal choroidal neovascularization ( CNV ) secondary AMD , include predominantly classic , minimally classic occult lesion , study eye . New diagnosis wet AMD evidence recent disease progression within last 3 month study eye . Evidence subretinal fluid retinal cystic change CSFT &gt; 340 μm use Spectralis SDOCT ( Heidelberg Engineering ) imaging system . Bestcorrected visual acuity ( BCVA ) Snellen equivalent 20/200 good nonstudy eye . Other protocoldefined inclusion criterion may apply . Previously administer therapy , approve investigational , wet AMD study eye . Any current history macular retinal disease stuy eye wet AMD . Lasik cataract surgery within last 3 month study eye expect cataract removal surgery study . Uncontrolled advanced glaucoma study eye . Use systemic topical ocular corticosteroid . History medical condition , opinion Investigator , would preclude scheduled visit , completion study , safe administration study medication . Abnormal unsuitable laboratory result Screening visit . Lactating pregnant . Women childbearing potential must use adequate birth control duration study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Exudative</keyword>
	<keyword>CNV</keyword>
</DOC>